Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL-Reference-Cited by-同舟云学术

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL

Published:2017-03-24 Issue:11 Volume:31 Page:2416-2425
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Howard D R^ORCID,Munir T,McParland L,Rawstron A C^ORCID,Milligan D,Schuh A,Hockaday A,Allsup D J^ORCID,Marshall S,Duncombe A S,O'Dwyer J L,Smith A F,Longo R,Varghese A,Hillmen P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu201796.pdf

Reference24 articles.

1. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127: 208–215.

2. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.

3. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do K-A et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980.

4. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

5. Keating M, O'Brien S . High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 2000; 27 (6 Suppl 12): 86–90.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region;Acta Haematologica;2023-09-26

2. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial;The Lancet Oncology;2023-05

3. A History of Targeted Therapy Development and Progress in Novel–Novel Combinations for Chronic Lymphocytic Leukemia (CLL);Cancers;2023-02-06

4. Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features;Nature Genetics;2022-11

5. Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II / III GALACTIC trial;British Journal of Haematology;2022-08-26